Stockchase Opinions

Stockchase InsightsJamieson WellnessJWEL.TOBUY ON WEAKNESSNov 25, 2020

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Business has reamiend good and earnings growth continues to be expected. They raised dividends in August with more room to grow. The $6 decline is probably over done. Unlock Premium - Try 5i Free

$32.50

Stock price when the opinion was issued

$35.53

As of Jun 05, 2026. Market Open.

0
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK

To "pump up" portfolios across Canada. Founded in Windsor ON. Bought a California company a few years ago, so little to no impact from tariffs. Growing in China, where company's attention to quality makes it stand apart. Seeing takeouts of private vitamin/mineral companies at much higher valuations. Has grown dividend over last 5 years at 14% clip. Yield is 2.55%.

(Analysts’ price target is $42.43)
BUY

Bottomed back in 2023. Since then a defined uptrend, with higher highs and higher lows. Chart looks good, stock remains in a trading range. Next upside target is ~$40.50.

WATCH

Good business, decent ROIC. Multiple's not inexpensive. Lots of retailers are available under 13x with great ROIC. He continues to meet with management.

HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

There has been no signficant recent company news, good or bad. It recently did get some upgrades, with TD noting 'strong contributions from the Chinese market, and no negative operational news'. The decline could be general small cap aversion or tariff fears, as we cannot point to anything specific here. The last quarter was mixed, but estimates have slowly ticked up over the last month. We would consider it OK, with high debt the main drawback for us. 
Unlock Premium - Try 5i Free

TOP PICK

Huge margins and free cashflow. Growing business annually compounded at over 15%. International expansion. US acquisition is growing double digits. Online China business growing 80%. Never been cheaper at 17x forward PE. Takeover potential in a few years. Yield is 2%.

(Analysts’ price target is $40.82)
HOLD

He owns it and likes it even though the price movement has been disappointing. It is consolidating here. Analysts have a $38 to$42 price target.

DON'T BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

EPS of 9c beat estimates of 6c; revenue of $128M beat estimates of $123.1M. EBITDA of $16M matched estimates. Year forecast was maintained. A couple of brokers lowered targets. Revenue fell 6.4% with a large decline in Strategic Partners business with the closing of a contract. Gross margins declined. While this was a 'beat' versus expectations, debt remains too high for our comfortable level, considering the fairly big decline in growth vs prior year. We think buyers can wait.
Unlock Premium - Try 5i Free

BUY
Adding to small- and mid-caps?

That's right. They've been severely beaten up over the last few years. Massive outflow of funds out of Canada, and it hits the smaller stocks even more. A lot of retail investors put in fund redemptions last year, so that created many bargains.

Over the last 6 months, he added to many of his small- and mid-cap positions. Companies like QTRH, JWEL, and EQB.

TOP PICK

Canada's #1 brand in its sector, has 25% market share. Went public 6-7 years ago, and increased sales and profits every year. US acquisition should accelerate growth. Now controls direct distribution in China. Cheaper than ever at 18x earnings, but growth prospects are better than ever. High margin, high quality, steady. Great entry point. Yield is 2.32%.

(Analysts’ price target is $43.53)
DON'T BUY

He sold it after a recent disappointing earnings report (lowered their guidance a lot). After all, they're not in a cyclical business. Their acquisition of a Chinese company was interesting, though the structure was unusual--they bought $100 million in preferred shares with warrants but no dividend and took a minority share in the Chinese business. That was the right move in the Chinese market. Otherwise, JWEL's fundamentals didn't impress him. The stock isn't getting much love these days.

PAST TOP PICK
(A Top Pick Jun 06/22, Down 20%)

Sold off, as investors assumed a pandemic bump. Sales continue to grow organically. Continues to gain market share. US acquisition lets them accelerate growth. Expanding dramatically in China. 19x earnings. Very high quality company.

BUY
Going forward, will be a large market for healthcare products. Aging population will ensure demand for products. Vitamins will help aging population. Healthcare will do well in the long term.
BUY
It's pulled back from its Covid highs, but there is a steady demand for vitamins. Pays a small dividend. There is upside potential when the market turns up, but steady during tough times.
BUY
Allan Tong’s Discover Picks Vitamins are defensive, something you need in today’s uncertain markets where the street keeps chattering about recession. The street likes JWEL stocks with seven buys and no holds or sells and expects about 30% upside at a $45.64 price target. JWEL stocks are still a ways off their $41.70 52-week high. Read Our 3 defensive healthcare stocks picks for our full analysis.
BUY ON WEAKNESS
A nice company that seems to dominate the vitamin business, which offers long-term growth. Buy this at a decent PE. People buy this when markets are uncertain. Buy below $35.